NOVO-NK

**NOVO-NK** is an investigational **autologous natural killer cell therapy** being developed by **Novocellbio**. It is described as an NK immune cell therapeutic generated from a patient's own immune cells, with the intended mechanism of restoring or augmenting innate cytotoxic activity against abnormal cells, including **tumor cells** and potentially **virus-infected cells**. Publicly available company-linked and press coverage indicates development in oncology, with a planned clinical program in cancer patients in South Korea, and exploratory work for **COVID-19** based on preclinical antiviral experiments. The available information does not clearly identify a single molecular target, standardized manufacturing product name beyond NOVO-NK, or a confirmed marketed status, so it is best characterized as an early-stage autologous NK cell immunotherapy candidate.